PTCT PTC Bio: Year-over-year earnings per share growth for the last twelve months

Official company branding of PTC Therapeutics (PTCT)

The absence of dividends for PTC Therapeutics, Inc. (PTCT) is offset by revenue growth from rare disease therapies and the approval of Upstaza. This quarterly earnings per share growth chart confirms business resilience, where the value of -416.70 expresses the metric level. Success is based on deep expertise in RNA biology and the creation of exclusive drugs. Trial scaling is facilitated through partnerships with leading contract research organizations that eliminate production disruptions.

PTC Therapeutics (PTCT) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/16/2026

Analytical breakdowns for PTC Therapeutics, Inc.

- share price and consensus valuation forecast:
Fundamental company analysis:ptcbio.com, PTCT
Manufactured product of PTC Bio

Analyzing net income per share is essential for assessing business resilience. This metric measures the rate of capital growth, isolating real operational success from one-time accounting adjustments. By examining the quarterly earnings per share chart, an investor can determine the effectiveness of margin management. For PTC Therapeutics, Inc. (PTCT), this indicator reflects the success of commercializing muscular dystrophy treatments and the development of gene therapy.

Analysis of competing companies

JAZZ (Jazz Pharmaceuticals PLC) - Year-over-year net earnings per share growth for the last 12 months|Cytokinetics Corp (CYTK) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Scholar Rock|CNTA: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Dyne Therapeutics (DYN)|EWTX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Rapport Pharma RAPP|Alumis Pharma - Year-over-year earnings per share growth for the last twelve months|ZVRA - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Contineum Therapeutics, Inc.|LRMR: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Capricor Therapeutics CAPR|Year-over-year net earnings per share growth for the last 12 months TRDA|Earnings per share growth in annualized terms for the last twelve months Channel PTHS|Year-over-year earnings per share growth for the last twelve months MediciNova Inc. (MNOV)|SER - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth BTAI (BioXcel Therapeutics Inc)|ProMIS Neurosciences (PMN) - Earnings per share growth in annualized terms for the last twelve months|Apimeds Pharmaceuticals, Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months AEON Biopharma, Inc.|NLSP (NLS Pharma) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months BNOX|Year-over-year earnings per share growth for the last twelve months FSD Pharma|Quarterly EPS earnings growth Reata